Smoking and serum CA19-9 levels according to Lewis and secretor genotypes

International Journal of Cancer

Volumn 123, Issue 12, 2008, Pages 2880-2884

  Kawai, Sayo ^a   Suzuki, Koji ^b   Nishio, Kazuko ^a   Ishida, Yoshiko ^a   Okada, Rieko ^a   Goto, Yasuyuki ^a   Naito, Mariko ^a   Wakai, Kenji ^a   Ito, Yoshinori ^a   Hamajima, Nobuyuki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

CA19 9; Lewis gene; Polymorphism; Secretor gene; Smoking

Indexed keywords

HEMOGLOBIN A1C; PROTEIN CA19-9; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BLOOD GROUP LEWIS SYSTEM; BODY MASS; CIGARETTE SMOKING; DNA POLYMORPHISM; DRINKING BEHAVIOR; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LEWIS GENE; MALE; MEDICAL EXAMINATION; NORMAL HUMAN; ONCOGENE; PRIORITY JOURNAL; PSEUDOGENE; SECRETOR SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ANALYSIS OF VARIANCE; ANTIGENS, NEOPLASM; BODY MASS INDEX; CA-19-9 ANTIGEN; FEMALE; GENOTYPE; HUMANS; JAPAN; LEWIS BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SECRETORY COMPONENT; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 57349159445     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23907     Document Type: Article

References (26)

1. Harder J, Kummer O, Olschewski M, Otto F, Blum HE, Opitz O. Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2097-100.
2. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95:204-7.
3. Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 1982;2:135-40.
4. Safi F, Roscher R, Bittner R, Schenkluhn B, Dopfer HP, Beger HG. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987;2:398-403.
5. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704-9.
6. Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998;77:325-8.
7. Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, Katz A, Simon SD, Gansl RC. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41.
8. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J. Biol Chem 1982;257:14365-9.
9. Nishihara S, Yazawa S, Iwasaki H, Nakazato M, Kudo T, Ando T, Narimatsu H. Alpha (1,3/1,4)fucosyltransferase (FucT-III) gene is inactivated by a single amino acid substitution in Lewis histo-blood type negative individuals. Biochem Biophys Res Commun 1993;196:624-31.
10. Nishihara S, Narimatsu H, Iwasaki H, Yazawa S, Akamatsu S, Ando T, Seno T, Narimatsu I. Molecular genetic analysis of the human Lewis histo-blood group system. J. Biol Chem 1994;269:29271-8.
11. Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, Sugano K, Okura H, Fujita S, Hirohashi S. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998;58:512-18.
12. Elmgren A, Börjeson C, Svensson L, Rydberg L, Larson G. DNA sequencing and screening for point mutations in the human Lewis (FUT3) gene enables molecular genotyping of the human Lewis blood group system. Vox Sang 1996;70:97-103.
13. Yu LC, Broadberry RE, Yang YH, Chen YH, Lin M. Heterogeneity of the human Secretor alpha(1,2)fucosyltransferase gene among Lewis(a+b-) non-secretors. Biochem Biophys Res Commun 1996;222:390-4.
14. Kudo T, Iwasaki H, Nishihara S, Shinya N, Ando T, Narimatsu I, Narimatsu H. Molecular genetic analysis of the human Lewis histo-blood group system. II. Secretor gene inactivation by a novel single missense mutation. A385T in Japanese nonsecretor individuals. J Biol Chem 1996;271:9830-7.
15. Uygur-Bayramicli O, Dabak R, Orbay E, Dolapcioglu C, Sargin M, Kilicoglu G, Guleryuzlu Y, Mayadagli A. Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol 2007;13:5357-9.
16. Hamajima N, Shibata A, Ikehara Y, Katsuda N, Mori S, Ito H, Matsuo K, Tajima K, Tominaga S. Lack of consistency in the associations of Helicobacter pylori seropositivity with Se and Le polymorphisms among Japanese Gastric Cancer 2002;5:194-200.
17. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H, Orntoft TF. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999;45:54-61.
18. Narimatsu H, Iwasaki H, Nishihara S, Kimura H, Kudo T, Yamauchi Y, Hirohashi S. Genetic evidence for the Lewis enzyme, which synthesizes type-1 Lewis antigens in colon tissue, and intracellular localization of the enzyme. Cancer Res 1996;56:330-8.
19. Ørntoft TF, Vestergaard EM, Holmes E, Jakobsen JS, Grunnet N, Mortensen M, Johnson P, Bross P, Gregersen N, Skorstengaard K, Jensen UB, Bolund L, et al. Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels. J Biol Chem 1996;271:32260-8.
20. Bloomston M, Bekaii-Saab TS, Kosuri K, Cowgill SM, Melvin WS, Ellison EC, Muscarella P II. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. Pancreas 2006;33:246-9.
21. Sasaki A, Kawano K, Inomata M, Shibata K, Matsumoto T, Kitano S. Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma. Hepatogastroenterology 2005;52:1814-19.
22. Dede M, Gungor S, Yenen MC, Alanbay I, Duru NK, Hasimi A. CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer 2006;16:189-93.
23. Aoki Y, Yanagisawa Y, Ohfusa H, Kawa S, Oguchi H, Furuta S. Elevation of serum CA 19-9 in parallel with HbA1c in a diabetic female with the Lewis(a+b-) blood group. Diabetes Res Clin Pract 1991;13:77-81.
24. van Leeuwen DM, Gottschalk RW, van Herwijnen MH, Moonen EJ, Kleinjans JC, van Delft JH. Differential gene expression in human peripheral blood mononuclear cells induced by cigarette smoke and its constituents. Toxicol Sci 2005;86:200-10.
25. Büttner P, Mosig S, Funke H. Gene expression profiles of T lymphocytes are sensitive to the influence of heavy smoking: a pilot study. Immunogenetics 2007;59:37-43.
26. Philibert RA, Ryu GY, Yoon JG, Sandhu H, Hollenbeck N, Gunter T, Barkhurst A, Adams W, Madan A. Transcriptional profiling of subjects from the Iowa adoption studies. Am J Med Genet B Neuropsychiatr Genet 2007;144:683-90.